A detailed history of Capital Counsel LLC transactions in Amgen Inc stock. As of the latest transaction made, Capital Counsel LLC holds 666 shares of AMGN stock, worth $214,898. This represents 0.01% of its overall portfolio holdings.

Number of Shares
666
Holding current value
$214,898
% of portfolio
0.01%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$262.75 - $319.31 $174,991 - $212,660
666 New
666 $208,000
Q2 2021

Aug 12, 2021

SELL
$233.58 - $259.14 $23,358 - $25,914
-100 Reduced 5.8%
1,625 $396,000
Q2 2020

Aug 14, 2020

BUY
$197.81 - $242.74 $19,781 - $24,274
100 Added 6.15%
1,725 $407,000
Q1 2019

May 15, 2019

SELL
$180.87 - $203.88 $17,544 - $19,776
-97 Reduced 5.63%
1,625 $309,000
Q2 2018

Aug 14, 2018

SELL
$166.05 - $186.51 $23,911 - $26,857
-144 Reduced 7.72%
1,722 $318,000
Q3 2017

Nov 14, 2017

BUY
$167.29 - $191.0 $312,163 - $356,406
1,866
1,866 $348,000

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $173B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Capital Counsel LLC Portfolio

Follow Capital Counsel LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Counsel LLC, based on Form 13F filings with the SEC.

News

Stay updated on Capital Counsel LLC with notifications on news.